Rate and predictors of loss to follow-up in HIV care in a low-resource setting: analyzing critical risk periods
Published in Biomedical Research
Why Do Some People Stop HIV Treatment? Understanding the Key Moments
In the global fight against HIV, keeping people engaged in their treatment is crucial. Even though many countries aim to meet ambitious HIV care goals by 2030, a significant challenge remains: helping those who start HIV treatment continue their care and keep their virus under control. A big part of this challenge is what’s known as "loss to follow-up" (LTFU).
What is Loss to Follow-Up (LTFU)?
LTFU happens when someone on HIV treatment misses their medical appointments or stops taking their medication for over 28 days. This is a serious issue, as it can lead to poorer health, increased risk of death, and a higher chance of spreading HIV to others because the virus isn’t being suppressed.
When Do People Stop Treatment?
This study looked at 737 adults who were new to HIV care and identified the times when they were most likely to stop their treatment:
- The First 6 Months Are Critical: About 50% of the people who dropped out of care did so within the first six months. This early period is a high-risk time, with an LTFU rate nine times higher than later periods (13-24 months). People might face challenges like dealing with side effects, struggling to adjust to a new routine, or not yet seeing the benefits of the medication.
- 7-12 Months: A Continued Risk: Even though the risk of dropping out decreases after the first six months, many people still struggle to stick with their treatment during months 7-12. About 30% of those who stopped care did so during this time. Factors like financial difficulties, stigma, or transportation issues can continue to affect them.
- After 12 Months: A More Stable Phase: After a year on treatment, the dropout rate drops significantly. By this time, many patients have adjusted to their routine, seen improvements in their health, and are more committed to their treatment.
What Can We Do About It?
The findings suggest that the first six months of HIV treatment are a make-or-break time. Health programs should focus on providing extra support during this period, such as helping patients manage side effects and offering counseling. Continued support is also important in the following months to help people overcome challenges that might come up later.
Follow the Topic
-
BMC Infectious Diseases
This journal is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans, as well as related molecular genetics, pathophysiology, and epidemiology.
Related Collections
With Collections, you can get published faster and increase your visibility.
Application of advanced statistical methods in infectious diseases 2025
BMC Infectious Diseases invites submissions for a Collection on Application of advanced statistical methods in infectious diseases.
The field of infectious diseases is rapidly evolving, with the advent of advanced statistical methods playing a crucial role in enhancing our understanding of disease dynamics, transmission patterns, and treatment outcomes. As we face a myriad of challenges from emerging and re-emerging infectious pathogens, the application of sophisticated statistical techniques—such as machine learning, Bayesian modeling, and network analysis—has become increasingly essential. This Collection aims to highlight innovative approaches that leverage these advanced methods to provide insights into infectious disease epidemiology, control measures, and public health interventions.
The significance of employing advanced statistical methods in infectious disease research cannot be understated. Recent advancements in big data analytics have enabled researchers to analyze large datasets that were previously unmanageable, leading to more accurate predictions and informed decision-making. By integrating real-time data from diverse sources, researchers can better understand disease outbreaks and assess the effectiveness of interventions. The ongoing refinement of statistical methodologies is paving the way for enhanced surveillance systems and targeted responses, ultimately improving public health outcomes.
As this field continues to evolve, future advancements may include the development of real-time analytics platforms that utilize artificial intelligence to forecast infectious disease trends. These innovations could lead to more proactive public health strategies, enabling quicker responses to emerging threats and more effective allocation of resources. Furthermore, the integration of genomics and environmental data with statistical models may provide unprecedented insights into the factors driving infectious disease transmission.
- Machine learning applications in infectious disease epidemiology
- Bayesian modeling for infectious disease prediction
- Big data statistics in outbreak analysis
- Network analysis of disease transmission
- Statistical methods for assessing treatment outcomes
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jan 31, 2026
Tuberculosis immunology and infection
BMC Infectious Diseases invites submissions for a Collection on Tuberculosis immunology and infection.
Tuberculosis (TB) remains a global health challenge, with millions affected by Mycobacterium tuberculosis each year. The interplay between the bacterium and the host's immune response is complex, involving various cellular and molecular mechanisms that determine the outcome of infection. Understanding the immunological aspects of TB is crucial for developing effective diagnostics, therapeutics, and vaccines. This Collection aims to explore the latest research on TB immunology, pathogenesis, and infection dynamics, shedding light on both latent and active TB states.
The significance of this research lies in its potential to inform public health strategies and interventions. Recent advances in immunological research and vaccine development have demonstrated promising avenues for tackling TB, including novel biomarkers for diagnosis and innovative vaccine candidates. Furthermore, the integration of genomic and proteomic technologies has provided deeper insights into the host-pathogen interactions, paving the way for more effective treatments and preventive measures. Continued focus on TB immunology will be vital in the global fight against this disease.
As research progresses, we anticipate breakthroughs that could transform TB management, including personalized vaccine strategies and targeted immunotherapies. The continued exploration of the immune response to TB may also yield critical insights into preventing reactivation of latent infections, ultimately contributing to the goal of TB eradication.
- Immune response to Mycobacterium tuberculosis
- Pathogenesis of latent and active TB
- Advances in TB vaccine development
- Novel diagnostic approaches for TB
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Dec 31, 2025
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in